Get In Touch

A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Liquid biopsy offers a real-time approach for the treatment of breast cancer. It is used for the collection and analysis of a sample of blood taken from the patient. Liquid biopsy uses body fluids as a sample for analysis, primarily blood. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, cell-free DNA (cfDNA) and their cargo proteins, and circulating cell-free RNA (cfRNA). A liquid biopsy is a noninvasive, simple, and cost-effective diagnostic tool for cancer. The amount of circulating biomarkers differ among cancer patients and healthy individuals. Therefore, these circulating biomarkers act as an important tool for both early diagnosis and monitoring of the progression of disease in advanced cancer stages to analyse the heterogeneity of tumor cells. Breast cancer is considered to be the second most common malignancy in the world, and therefore, liquid biopsy is a very important tool for breast cancer diagnosis and determination.

According to the World Health Organization (WHO), breast cancer is the most frequently occurring cancer among women. It affects 2.1 million women each year and results in the highest number of cancer-related deaths among women. In 2018, it was evaluated that 627,000 women died from breast cancer, i.e. around 15% of all cancer-related deaths among women. While rates of breast cancer are higher among women in more developed regions, rates are elevating in nearly every region globally.

Key drivers of the breast cancer liquid biopsy market include rise in the prevalence of breast cancer, increase in propensity for non-invasive procedures, rise in awareness about cancer, increase in health care expenditure,  and initiatives and measures taken by government and global health organizations. Moreover, intensive research and development in the field of cancer, technological advancements, and an inclination toward personalized medicine are expected to enhance the growth of the market. However, insufficiency of trained professionals, high cost of the tests, and fewer reimbursement policies are expected to hinder the global breast cancer liquid biopsy market.

Based on circulating biomarkers, the global breast cancer liquid biopsy market can be classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other circulating biomarkers. The cell-free DNA (cfDNA) segment is expected to hold a prominent share of the breast cancer liquid biopsy market. This is because of rise in research in breast cancer using cfDNA for the diagnosis of the disease and therapeutic monitoring. In terms of end-user, the global breast cancer liquid biopsy market can be categorized into reference laboratories, hospitals and physician laboratories, and other end-users. Other end-users comprise research institutes, academic research laboratories, pathology laboratories, etc. Reference laboratories is expected to be a prominent end-user segment, accounting for a significant share of the breast cancer liquid biopsy market. This is due to a rise in the number of liquid biopsy test samples received by reference laboratories for genetic testing because of their well-equipped set-up.

Based on geography, the global breast cancer liquid biopsy market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.  North America and Europe accounted for a prominent share of the global breast cancer liquid biopsy market due to the presence of a number of biopharmaceutical companies research and academic institutes. Asia Pacific is expected to be a rapidly expanding region of the breast cancer liquid biopsy market due to a large population base, increased prevalence of cancer, and rise in investments by leading market players and hospitals.

Key players operating in the global breast cancer liquid biopsy market are Qiagen, Bio-Rad Laboratories, Inc.,  F. Hoffmann-La Roche Ltd,  Myriad Genetics, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Genomic Health, Menarini Silicon Biosystems, Cynvenio Biosystems, Inc., Guardant Health, INC , Biodesix, Inc., and Isogen Life Science B.V. among others. In order to gain a competitive advantage in the market, key players are actively involved in various growth strategies such as agreements, partnerships and collaborations, and new product development.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Breast Cancer Liquid Biopsy Market

Pre Book